NASDAQ$GOCO
GoHealth Inc · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
GoHealth reported its financial results for the first quarter ended March 31, 2025, showing significant improvements in revenue, net loss, and Adjusted EBITDA compared to the prior year.
GoHealth, Inc. announced strong first quarter 2025 results with net revenues increasing by 19.1% to $221.0 million and a significant improvement in net loss, which decreased by 54.2% to $9.8 million. Adjusted EBITDA saw a substantial 56.4% increase to $42.1 million, driven by higher submissions and improved operating efficiency.
- Net revenues for Q1 2025 increased by 19.1% to $221.0 million.
- Net loss improved by 54.2% to $9.8 million in Q1 2025.
- Adjusted EBITDA grew by 56.4% to $42.1 million.
- Submissions increased by 40.2% to 303,026, primarily due to strong contributions from internal captive agents.
Headline financials
Revenue & EPS history
GoHealth · Revenue · Quarterly
$221M
Revenue by segment
GoHealth · $11.9M total across 4 segments · Q1 2026
- Medicare Agency Revenue$9.8M—82.2%
- Other Non-Agency Revenue$1.76M—14.8%
- Medicare Non-Agency Revenue$200K—1.7%
- Other Agency Revenue$155K—1.3%
Forward guidance
The company did not provide specific forward-looking financial guidance in this report. However, the CEO and CFO expressed optimism about continued momentum and strategic investments.
Tailwinds
- Continued refinement of platform, tools, product offerings, and technology to enhance consumer experience.
- Diversification of product offerings with the launch of GoHealth Protect, including guaranteed acceptance life insurance.
- Expectation that the new GoHealth Protect offering will enhance cash flow generation and reduce acquisition costs across the business.
- Commitment to disciplined execution and smart investment for continued momentum.
- Focus on extending customer relationships and bolstering unit economics.
Headwinds
- No specific negative forward guidance was provided in the report.
- The company acknowledges that forward-looking statements are subject to risks, assumptions, and uncertainties.
- Actual results may differ materially from expectations.
- Future periods may include income and expenses similar to excluded items in non-GAAP measures.
- The company does not plan to publicly update or revise forward-looking statements unless required by applicable law.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2025
-7.7%
Avg return
Earnings day
-9.0%
Avg return
5 days after
-6.6%
Avg return
30 days after
26%
6 / 23 earnings
Positive
+32.2%
Q1 2023
Best reaction
-45.5%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.5% | — | — | |
| Q3 2025 | -24.4% | -32.0% | -12.8% | |
| Q2 2025 | -9.0% | -7.6% | -23.8% | |
| Q1 2025 | -0.6% | -17.4% | -21.4% | |
| Q4 2024 | -14.4% | -14.9% | -32.8% | |
| Q3 2024 | -6.6% | -0.4% | -15.4% | |
| Q2 2024 | -21.4% | -28.3% | -34.0% | |
| Q1 2024 | -8.0% | -11.1% | +2.2% | |
| Q4 2023 | -13.0% | -25.7% | -27.0% | |
| Q3 2023 | +2.3% | +6.7% | +7.4% | |
| Q2 2023 | +6.8% | +6.3% | -17.2% | |
| Q1 2023 | +32.2% | +44.8% | +99.5% | |
| Q4 2022 | -19.9% | -6.2% | -18.5% | |
| Q3 2022 | -16.7% | -9.4% | +95.3% | |
| Q2 2022 | -31.5% | -43.3% | -57.0% | |
| Q1 2022 | +11.1% | +4.9% | +6.5% | |
| Q4 2021 | +23.7% | +37.7% | -9.8% | |
| Q3 2021 | +1.1% | -4.7% | -18.1% | |
| Q2 2021 | -45.5% | -42.2% | -34.7% | |
| Q1 2021 | -2.7% | -5.6% | -4.0% | |
| Q4 2020 | -14.9% | -16.9% | -4.1% | |
| Q3 2020 | -14.9% | -15.1% | +1.8% | |
| Q2 2020 | -10.5% | -18.5% | -27.1% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro